{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:34:17Z","timestamp":1780590857668,"version":"3.54.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Ministero dell&apos;Istruzione dell&apos;Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN 2022 5LKPYA"],"award-info":[{"award-number":["PRIN 2022 5LKPYA"]}],"id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2019"],"award-info":[{"award-number":["IG 2019"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["22837 IG 2025-ID 31958"],"award-info":[{"award-number":["22837 IG 2025-ID 31958"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.biopha.2026.119185","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:41:57Z","timestamp":1773254517000},"page":"119185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Synthesis and characterization of new P2X7 receptor antagonists as antitumor agents"],"prefix":"10.1016","volume":"197","author":[{"given":"Marianna","family":"Grignolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5172-651X","authenticated-orcid":false,"given":"Andrea","family":"Spinaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pegoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Ruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-1531","authenticated-orcid":false,"given":"Catia","family":"Lambertucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0360-4304","authenticated-orcid":false,"given":"Daniele","family":"Vitone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Leopoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2443-1174","authenticated-orcid":false,"given":"Enza","family":"Lacivita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8383-0813","authenticated-orcid":false,"given":"Michela","family":"Buccioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Francucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Marucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Dal","family":"Ben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5304-5232","authenticated-orcid":false,"given":"Rosaria","family":"Volpini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8129-9929","authenticated-orcid":false,"given":"Elena","family":"Adinolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biopha.2026.119185_bib1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.tcb.2018.01.005","article-title":"The Elusive P2X7 macropore","volume":"28","author":"Di Virgilio","year":"2018","journal-title":"Trends Cell Biol."},{"issue":"1700","key":"10.1016\/j.biopha.2026.119185_bib2","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2015.0427","article-title":"P2X receptors","volume":"371","author":"North","year":"2016","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119185_bib3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1152\/physrev.00015.2002","article-title":"Molecular physiology of P2X receptors","volume":"82","author":"North","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2026.119185_bib4","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.22153","article-title":"Structural basis for subtype-specific inhibition of the P2X7 receptor","volume":"5","author":"Karasawa","year":"2016","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.biopha.2026.119185_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1574892814666190116122256","article-title":"Purinergic P2X7 receptor: a cation channel sensitive to tumor microenvironment","volume":"14","author":"Scarpellino","year":"2019","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.biopha.2026.119185_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-018-0037-0","article-title":"Extracellular ATP and P2 purinergic signalling in the tumour microenvironment","author":"Di Virgilio","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.biopha.2026.119185_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813906","article-title":"The P2X7 receptor in oncogenesis and metastatic dissemination: new insights on vesicular release and adenosinergic crosstalk","volume":"24","author":"Adinolfi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2026.119185_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25126673","article-title":"P2X7 variants in pathophysiology","volume":"25","author":"Pegoraro","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119185_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149513","article-title":"The impact of the P2X7 receptor on the tumor immune microenvironment and its effects on tumor progression","volume":"707","author":"Zou","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2026.119185_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071782","article-title":"Cancer metabostemness and metabolic reprogramming via P2X7 receptor","volume":"10","author":"Rabelo","year":"2021","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.biopha.2026.119185_bib11","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1158\/0008-5472.CAN-11-1947","article-title":"Expression of P2X7 receptor increases in vivo tumor growth","volume":"72","author":"Adinolfi","year":"2012","journal-title":"Cancer Res."},{"issue":"41","key":"10.1016\/j.biopha.2026.119185_bib12","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1038\/onc.2014.444","article-title":"The P2X7 receptor is a key modulator of the PI3K\/GSK3beta\/VEGF signaling network: evidence in experimental neuroblastoma","volume":"34","author":"Amoroso","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119185_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3389\/fphar.2020.00793","article-title":"P2X7 in cancer: from molecular mechanisms to therapeutics","volume":"11","author":"Lara","year":"2020","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2026.119185_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1012534","article-title":"Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo","volume":"13","author":"Demeules","year":"2022","journal-title":"Front. Immunol."},{"issue":"18","key":"10.1016\/j.biopha.2026.119185_bib15","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/onc.2010.593","article-title":"P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness","volume":"30","author":"Jelassi","year":"2011","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.biopha.2026.119185_bib16","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/carcin\/bgt099","article-title":"Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors","volume":"34","author":"Jelassi","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2026.119185_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coph.2016.05.001","article-title":"P2 receptors in cancer progression and metastatic spreading","volume":"29","author":"Di Virgilio","year":"2016","journal-title":"Curr. Opin. Pharm."},{"issue":"12","key":"10.1016\/j.biopha.2026.119185_bib18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41419-021-04378-0","article-title":"P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells","volume":"12","author":"Pegoraro","year":"2021","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.biopha.2026.119185_bib19","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1097\/JS9.0000000000002406","article-title":"P2X7 receptor promotes the growth and metastasis of gastric cancer by activating P13\/AKT\/GSK-3 beta signaling (experimental research)","volume":"111","author":"Zhang","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.biopha.2026.119185_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.876510","article-title":"A2A receptor contributes to tumor progression in P2X7 null mice","volume":"10","author":"De Marchi","year":"2022","journal-title":"Front Cell Dev. Biol."},{"issue":"21","key":"10.1016\/j.biopha.2026.119185_bib21","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2174\/0929867324666170303161659","article-title":"P2X7 receptor orchestrates multiple signalling pathways triggering inflammation, autophagy and metabolic\/trophic responses","volume":"24","author":"Orioli","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119185_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108700","article-title":"Overview of the role of purinergic signaling and insights into its role in cancer therapy","volume":"262","author":"Di Virgilio","year":"2024","journal-title":"Pharm. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119185_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41419-025-07897-2","article-title":"P2X7 a new therapeutic target to block vesicle-dependent metastasis in colon carcinoma: role of the A2A\/CD39\/CD73 axis","volume":"16","author":"Pegoraro","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119185_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","article-title":"The P2X7 receptor in Infection and Inflammation","volume":"47","author":"Di Virgilio","year":"2017","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.biopha.2026.119185_bib25","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.4049\/jimmunol.2000222","article-title":"The expression of P2X7 receptor on Th1, Th17, and regulatory T cells in patients with systemic lupus erythematosus or rheumatoid arthritis and its correlations with active disease","volume":"205","author":"Li","year":"2020","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119185_bib26","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240354","article-title":"Selective regulation of IFN-gamma and IL-4 co-producing unconventional T cells by purinergic signaling","volume":"221","author":"Xu","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2026.119185_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41388-019-0684-y","article-title":"The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment","author":"De Marchi","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119185_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2019.02.012","article-title":"Role of the P2X7 receptor in tumor-associated inflammation","volume":"47","author":"Adinolfi","year":"2019","journal-title":"Curr. Opin. Pharm."},{"key":"10.1016\/j.biopha.2026.119185_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.694831","article-title":"The P2X7 Receptor in Tumor Immunity.","volume":"9","author":"Grassi","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2026.119185_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1006384","article-title":"Emerging roles of purinergic signaling in anticancer therapy resistance","volume":"10","author":"Zanoni","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2026.119185_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-0716-2384-8_2","article-title":"Agonists, antagonists, and modulators of P2X7 receptors","volume":"2510","author":"Muller","year":"2022","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119185_bib32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjd.15364","article-title":"A phase I clinical trial demonstrates that nfP2X7 -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma","volume":"177","author":"Gilbert","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119185_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1512","article-title":"Engineered CAR-T cells targeting the non-functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer","volume":"13","author":"Bandara","year":"2024","journal-title":"Clin. Transl. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119185_bib34","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2174\/0929867330666230403094538","article-title":"Structure-activity relationships and therapeutic potential of purinergic P2X7 receptor antagonists","volume":"31","author":"El Idrissi","year":"2024","journal-title":"Curr. Med. Chem."},{"issue":"11","key":"10.1016\/j.biopha.2026.119185_bib35","doi-asserted-by":"crossref","first-page":"8199","DOI":"10.1016\/S0021-9258(18)53082-9","article-title":"Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor","volume":"268","author":"Murgia","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119185_bib36","first-page":"82","article-title":"Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors","volume":"58","author":"Jiang","year":"2000","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.biopha.2026.119185_bib37","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/sj.bjp.0701081","article-title":"The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes","volume":"120","author":"Gargett","year":"1997","journal-title":"Br. J. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2026.119185_bib38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.bjp.0705470","article-title":"Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms","volume":"140","author":"Beigi","year":"2003","journal-title":"Br. J. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2026.119185_bib39","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1476-5381.2009.00233.x","article-title":"Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors","volume":"157","author":"Donnelly-Roberts","year":"2009","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119185_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fendo.2012.00041","article-title":"The P2X7 receptor is an important regulator of extracellular ATP Levels","volume":"3","author":"Brandao-Burch","year":"2012","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2026.119185_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114394","article-title":"Nanobodies as probes to investigate purinergic signaling","volume":"187","author":"Eggers","year":"2021","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.biopha.2026.119185_bib42","unstructured":"W. Carroll, A. F, A. Perez-Medrano, S. PeddiP2X7 receptor antagonists and methods of use, Patent: US20070105842A12007."},{"key":"10.1016\/j.biopha.2026.119185_bib43","unstructured":"J.P. Kilburn, L.K. Rasmussen, M. Jessing, E.M. Eldemenky, B. Chen, Y. Jiang, 2014, Cyclic amines, Patent: US0107335A1: United States 2014."},{"issue":"6","key":"10.1016\/j.biopha.2026.119185_bib44","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.bmcl.2008.01.095","article-title":"synthesis and in vitro activity of 1-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine and 4-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine P2X7 antagonists","volume":"18","author":"Florjancic","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5262","key":"10.1016\/j.biopha.2026.119185_bib45","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.272.5262.735","article-title":"The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7)","volume":"272","author":"Surprenant","year":"1996","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.biopha.2026.119185_bib46","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1124\/jpet.106.111559","article-title":"A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat","volume":"319","author":"Honore","year":"2006","journal-title":"J. Pharm. Exp. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2026.119185_bib47","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1091\/mbc.e04-11-1025","article-title":"Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth","volume":"16","author":"Adinolfi","year":"2005","journal-title":"Mol. Biol. Cell"},{"issue":"9","key":"10.1016\/j.biopha.2026.119185_bib48","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1096\/fj.09-153601","article-title":"Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor","volume":"24","author":"Adinolfi","year":"2010","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119185_bib49","doi-asserted-by":"crossref","first-page":"8283","DOI":"10.1038\/s41467-025-62643-8","article-title":"A polycyclic scaffold identified by structure-based drug design effectively inhibits the human P2X7 receptor","volume":"16","author":"Oken","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119185_bib50","unstructured":"Molecular Operating Environment (MOE). 2025, C.C.G., Inc., 1255 University St., Suite 1600, Montreal, Quebec, Canada, H3B 3\u00d73."},{"issue":"40","key":"10.1016\/j.biopha.2026.119185_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado5084","article-title":"P2X(7) receptors exhibit at least three modes of allosteric antagonism","volume":"10","author":"Oken","year":"2024","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.biopha.2026.119185_bib52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J. Pharm. Exp. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2026.119185_bib53","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2174\/138620708784911429","article-title":"Applications of high throughput microsomal stability assay in drug discovery","volume":"11","author":"Di","year":"2008","journal-title":"Comb. Chem. High. Throughput Screen"},{"key":"10.1016\/j.biopha.2026.119185_bib54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/bs.mie.2019.07.043","article-title":"structure, function and techniques of investigation of the P2X7 receptor (P2X7R) in mammalian cells","volume":"629","author":"Di Virgilio","year":"2019","journal-title":"Methods Enzym."},{"issue":"3","key":"10.1016\/j.biopha.2026.119185_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167611","article-title":"Retinoic acid-induced alterations enhance eATP-mediated anticancer effects in glioma cells: implications for P2X7 receptor variants as key players","volume":"1871","author":"Szymczak","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"7","key":"10.1016\/j.biopha.2026.119185_bib56","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2174\/0929867321666141012172913","article-title":"Emerging roles of P2X receptors in cancer","volume":"22","author":"Adinolfi","year":"2015","journal-title":"Curr. Med. Chem."},{"issue":"1-3","key":"10.1016\/j.biopha.2026.119185_bib57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2012.09.001","article-title":"Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7","volume":"695","author":"Hattori","year":"2012","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119185_bib58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.canlet.2017.05.004","article-title":"Roles of purinergic P2X7 receptor in glioma and microglia in brain tumors","volume":"402","author":"McLarnon","year":"2017","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2026.119185_bib59","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41419-022-04526-0","article-title":"Irradiation causes senescence, ATP release, and P2X7 receptor isoform switch in glioblastoma","volume":"13","author":"Zanoni","year":"2022","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.biopha.2026.119185_bib60","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1158\/0008-5472.CAN-14-1259","article-title":"Accelerated tumor progression in mice lacking the ATP receptor P2X7","volume":"75","author":"Adinolfi","year":"2015","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2026.119185_bib61","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/jnc.12031","article-title":"Activation of the P2X(7) receptor induces migration of glial cells by inducing cathepsin B degradation of tissue inhibitor of metalloproteinase 1","volume":"123","author":"Murphy","year":"2012","journal-title":"J. Neurochem."},{"issue":"12","key":"10.1016\/j.biopha.2026.119185_bib62","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1182\/blood-2005-07-2994","article-title":"Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor","volume":"107","author":"Gu","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.biopha.2026.119185_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413691","article-title":"The complex role of matrix metalloproteinase-2 (MMP-2) in health and disease","volume":"25","author":"Wolosowicz","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119185_bib64","article-title":"Inhibiting extracellular vesicles formation and release: a review of EV inhibitors","volume":"9","author":"Catalano","year":"2020","journal-title":"J. Extra Vesicles"},{"issue":"4","key":"10.1016\/j.biopha.2026.119185_bib65","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18138","article-title":"Exosome inhibition improves response to first-line therapy in small cell lung cancer","volume":"28","author":"Irep","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.biopha.2026.119185_bib66","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-1-4939-9717-6_13","article-title":"Detection of extracellular ATP in the tumor microenvironment, using the pmeLUC biosensor","volume":"2041","author":"De Marchi","year":"2020","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119185_bib67","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41388-022-02561-x","article-title":"Interferon-gamma signaling promotes melanoma progression and metastasis","volume":"42","author":"Zhou","year":"2023","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2026.119185_bib68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","article-title":"Overcoming TGFbeta-mediated immune evasion in cancer","volume":"22","author":"Tauriello","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2026.119185_bib69","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2967\/jnumed.118.212696","article-title":"Preclinical evaluation and nonhuman primate receptor occupancy study of (18)F-JNJ-64413739, a PET radioligand for P2X7 receptors","volume":"60","author":"Kolb","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119185_bib70","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.bmcl.2008.01.094","article-title":"Synthesis and in vitro activity of N\u2032-cyano-4-(2-phenylacetyl)-N-o-tolylpiperazine-1-carboximidamide P2X7 antagonists","volume":"18","author":"Morytko","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.biopha.2026.119185_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107224","article-title":"Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma","volume":"9","author":"Giuliani","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2026.119185_bib72","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/978-1-0716-2384-8_17","article-title":"Administration of P2X7 receptor blockers in oncological experimental models","volume":"2510","author":"De Marchi","year":"2022","journal-title":"Methods Mol. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119185_bib73","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","article-title":"Guidelines for the welfare and use of animals in cancer research","volume":"102","author":"Workman","year":"2010","journal-title":"Br. J. Cancer"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:53:15Z","timestamp":1776135195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226002180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":73,"alternative-id":["S0753332226002180"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119185","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and characterization of new P2X7 receptor antagonists as antitumor agents","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119185"}}